INTRODUCTION: We previously reported the prognostic significance of the @entity2220 immune microenvironment. In this study, we preformed comprehensive analysis of immune markers and their associations with prognosis in @entity1 with @entity957 . METHODS: We reviewed surgically resected, solitary @entity957 @entity1 (n = 485; 1999-2009) who were randomly split into a training cohort (n = 331) and validation cohort (n = 154). We constructed tissue microarrays and performed immunostaining for CD3, CD45RO, @entity405 , @entity404 , @entity403 , @entity2225 , @entity469 , @entity1570 , @entity436 , @entity9350 , @entity6978 . @entity1349 ( @entity1349 ) was analyzed using the log-rank test and the Cox proportional hazards model. RESULTS: Analysis of single immune cell infiltration revealed that high @entity5 -infiltrating @entity2282 (+) neutrophils were associated with worse prognoses in the training cohort (p = 0.021). Analysis of biologically relevant immune cell combinations identified that @entity1 with high @entity2282 neutrophil and low @entity2225 (+) lymphocyte had a significantly worse @entity1349 (5-year @entity1349 , 42%) than those with other combinations of @entity2282 and @entity2225 (5-year @entity1349 , 62%; p < 0.001); this was confirmed in the validation cohort (p = 0.032). For the multivariate analysis, high @entity2282 /low @entity2225 immune cell infiltration was an independent predictor of @entity1349 in both the training cohort (hazard ratio = 1.61, p = 0.006) and the validation cohort (hazard ratio = 1.75; p = 0.043). CONCLUSION: High @entity2282 (+)/low @entity2225 (+) immune cell infiltration ratio is a significant prognostic factor of @entity957 . Immunomodulatory therapy of @entity5 -specific neutrophil and B-lymphocyte responses may have applicability in the treatment of @entity957 .

Prognostic Impact of Immune Microenvironment in XXXX : Tumor-Infiltrating @entity2282 + Neutrophil/ @entity2225 + Lymphocyte Ratio as an Independent Prognostic Factor.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity957 :: ('MESH:D002294', 'Disease') :: ['lung squamous cell carcinoma'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity469 :: ('968', 'Gene') :: ['CD68'] @entity405 :: ('925', 'Gene') :: ['CD8'] @entity1570 :: ('6387', 'Gene') :: ['CXCL12'] @entity6978 :: ('3575', 'Gene') :: ['interleukin-7 receptor, and interleukin-12 receptor b2'] @entity2282 :: ('4311', 'Gene') :: ['CD10'] @entity403 :: ('50943', 'Gene') :: ['FoxP3'] @entity9350 :: ('1236', 'Gene') :: ['CCR7'] @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'Overall survival'] @entity436 :: ('7852', 'Gene') :: ['CXCR4']
@entity957 :: (MESH:D002294,Disease) :: ['Lung Squamous Cell Carcinoma']
